Global Angiogenesis Inhibitors Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Angiogenesis Inhibitors Market Overview

The Angiogenesis Inhibitors Market was valued at USD 25.00 billion in 2025 and is projected to reach USD 50.54 billion by 2033, growing at a CAGR of 9.20% from 2026 to 2033. The Angiogenesis Inhibitors Market is experiencing steady growth driven by the rising global burden of chronic diseases, particularly cancer, increasing research in targeted therapies, and rapid advancements in biotechnology and molecular drug development. Expanding understanding of tumor angiogenesis mechanisms and the growing shift toward precision medicine are further accelerating the adoption of angiogenesis inhibitors across oncology treatment protocols.

The increasing incidence of Cancer worldwide, coupled with rising healthcare expenditure and supportive regulatory approvals for novel biologics, is encouraging pharmaceutical companies and research institutions to invest heavily in anti-angiogenic drug development. In addition, growing use of combination therapies, improved clinical trial outcomes, and expanding access to advanced oncology treatments in both developed and emerging markets are further driving market expansion. Key Market Trends & Insights

• North America dominated the Angiogenesis Inhibitors Market with the largest revenue share of 38.92% in 2025, supported by strong oncology drug adoption, advanced healthcare infrastructure, and high R&D investments by leading pharmaceutical companies.
• The Parenteral segment dominated the market with a 72.64% share in 2025 due to the widespread use of injectable biologics and monoclonal antibodies in cancer treatment.
• Asia-Pacific is expected to be the fastest-growing region at a CAGR of 7.8% from 2026 to 2033, fueled by rising cancer prevalence, improving access to biologics, and increasing healthcare spending across China, India, and Japan.
• Among indications, Colorectal Cancer dominated the market with a 34.27% revenue share in 2025, owing to high incidence rates and strong adoption of anti-angiogenic therapies in treatment protocols.
• The Parenteral route of administration held the largest share of 72.64% in 2025, driven by the widespread use of intravenous biologics such as monoclonal antibodies in hospital-based cancer care settings.
• Hospital Pharmacies accounted for the dominant distribution channel with a 55.18% share in 2025, supported by high patient inflow in oncology departments and centralized dispensing of advanced biologic therapies.

Market Size & Forecast

• Global Market Value (2025): USD 25.00 Billion
• Expected Market Value (2033): USD 50.54 Billion
• Forecast CAGR (2026–2033): 9.20%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia-Pacific

Report Scope and Angiogenesis Inhibitors Market Segmentation

Angiogenesis Inhibitors Market Trends

Trend: Growing Adoption of Combination Cancer Therapies

Angiogenesis inhibitors are increasingly being used in combination with immunotherapies, targeted therapies, and chemotherapy regimens to improve clinical outcomes across multiple cancer indications. Combination approaches help overcome treatment resistance, enhance progression-free survival, and improve overall response rates in patients with advanced cancers. Pharmaceutical companies are actively expanding clinical trials evaluating anti-angiogenic agents alongside immune checkpoint inhibitors and precision oncology treatments. For instance, combinations involving bevacizumab and immunotherapy have demonstrated favorable outcomes in several solid tumors, encouraging broader adoption of multi-modal treatment strategies. This trend is expected to support sustained demand for angiogenesis inhibitors as oncology treatment paradigms continue to evolve toward personalized and combination-based care.

Angiogenesis Inhibitors Market Dynamics

Key Market Driver: Rising Global Cancer Burden and Demand for Targeted Therapies

The increasing incidence of cancer worldwide is a major driver for the angiogenesis inhibitors market. According to international cancer statistics, millions of new cancer cases are diagnosed annually, creating substantial demand for advanced targeted therapies that can inhibit tumor growth and metastasis. Angiogenesis inhibitors have become an important component of treatment protocols for colorectal cancer, renal cell carcinoma, glioblastoma, hepatocellular carcinoma, and other malignancies. The growing preference for targeted therapies over conventional treatment approaches, coupled with expanding regulatory approvals for anti-angiogenic drugs, is further accelerating market growth. Continuous investments in oncology research and precision medicine are also supporting the development and commercialization of novel angiogenesis inhibitor therapies.

Key Restraint/Challenge: High Treatment Costs and Therapy Resistance

A significant challenge in the Angiogenesis Inhibitors Market is the high cost associated with biologic therapies and targeted cancer treatments. Many anti-angiogenic drugs require prolonged treatment durations, increasing the overall financial burden on healthcare systems and patients. In addition, the development of drug resistance remains a major clinical concern, as tumors may activate alternative angiogenic pathways that reduce treatment effectiveness over time. Adverse effects such as hypertension, bleeding complications, and impaired wound healing can further limit long-term therapy utilization. These factors create barriers to widespread adoption, particularly in low- and middle-income countries where access to advanced oncology treatments remains constrained.

Key Market Opportunity: Development of Next-Generation Anti-Angiogenic Therapies

The development of next-generation angiogenesis inhibitors presents a significant market opportunity. Pharmaceutical and biotechnology companies are investing heavily in novel molecules, biosimilars, and combination therapies designed to improve efficacy and overcome resistance mechanisms. Increasing research into VEGF, FGF, and other angiogenic signaling pathways is expanding the potential therapeutic landscape. In addition, the growing use of biomarkers and precision medicine approaches is enabling more targeted patient selection, improving treatment outcomes and commercial prospects. Expanding clinical trial activity and rising approvals of innovative oncology drugs across emerging markets are expected to create substantial growth opportunities for industry participants throughout the forecast period.

Angiogenesis Inhibitors Market Scope

The Angiogenesis Inhibitors market is segmented on the basis of product, indication, drugs, route of administration, end-users, and distribution channel.

• By Product

On the basis of product, the Angiogenesis Inhibitors Market is segmented into VEGF Targeted Therapy, FGF Targeted Therapies, Oncogene Targeted Therapy, Matrix Degrading and Remodeling Targeted Therapy, and Others. The VEGF Targeted Therapy segment dominated the market with a 47.36% share in 2025 due to its widespread use across multiple oncology indications and its proven effectiveness in inhibiting tumor blood vessel formation. The segment benefits from strong clinical evidence supporting its application in colorectal cancer, renal cell carcinoma, lung cancer, and other solid tumors. Increasing adoption of targeted cancer therapies, favorable reimbursement policies, and strong physician preference for VEGF inhibitors have supported market growth. The availability of established biologics and biosimilars has further expanded patient access to treatment. Growing investments in oncology drug development and continuous regulatory approvals have strengthened segment demand. In addition, the increasing use of VEGF inhibitors in combination therapy regimens has improved treatment outcomes and expanded their clinical applications. Rising cancer incidence globally and expanding healthcare infrastructure are further supporting adoption. These factors collectively contributed to the segment's dominant market position in 2025.

The FGF Targeted Therapies segment is expected to witness the fastest CAGR of 8.1% from 2026 to 2033. Growth is driven by increasing research focused on fibroblast growth factor pathways and their role in cancer progression. Pharmaceutical companies are investing heavily in next-generation targeted therapies designed to address treatment resistance and improve patient outcomes. Expanding clinical trial activities and growing interest in precision medicine are creating favorable opportunities for segment expansion. The increasing identification of molecular biomarkers is enabling better patient selection and treatment personalization. Rising demand for innovative therapies with enhanced efficacy profiles is further supporting growth. Technological advancements in oncology research and drug discovery continue to accelerate product development. Growing healthcare expenditure and increasing access to advanced cancer treatments across emerging markets are also contributing to adoption. These factors are expected to drive strong growth throughout the forecast period.

• By Indication

On the basis of indication, the Angiogenesis Inhibitors Market is segmented into Glioblastoma, Colorectal Cancer, and Others. The Colorectal Cancer segment dominated the market with a 39.84% share in 2025 due to the high prevalence of the disease worldwide and the extensive use of angiogenesis inhibitors in treatment protocols. The segment benefits from growing awareness regarding early diagnosis and increasing availability of targeted therapies. Anti-angiogenic drugs are widely incorporated into colorectal cancer treatment regimens to improve progression-free survival and treatment outcomes. Rising healthcare expenditure and strong adoption of advanced oncology therapies have further supported segment growth. Continuous clinical research and favorable treatment guidelines are encouraging the use of angiogenesis inhibitors in colorectal cancer management. Increasing screening programs and expanding access to cancer care services have also contributed to higher treatment rates. The growing burden of colorectal cancer across developed and developing economies continues to strengthen demand. These factors collectively supported the segment’s leading market position in 2025.

The Glioblastoma segment is projected to register the fastest CAGR of 7.8% from 2026 to 2033. Growth is attributed to increasing research focused on brain cancer treatment and the urgent need for effective therapies for aggressive tumors. Angiogenesis inhibitors play an important role in controlling tumor vascularization in glioblastoma patients. Rising investments in neuro-oncology research and expanding clinical trials are supporting market growth. Pharmaceutical companies are developing innovative treatment approaches to improve patient survival outcomes. Growing adoption of targeted therapies and precision medicine strategies is further driving segment expansion. Improvements in diagnostic technologies and increasing awareness among healthcare providers are contributing to earlier treatment initiation. Expanding healthcare infrastructure and supportive regulatory initiatives are expected to accelerate market growth. These factors are anticipated to support strong segment expansion during the forecast period.

• By Drugs

On the basis of drugs, the Angiogenesis Inhibitors Market is segmented into Inlyta, Avastin, Revlimid, and Others. The Avastin segment dominated the market with a 36.92% share in 2025 due to its extensive clinical use across multiple cancer indications and its established efficacy in anti-angiogenic therapy. The drug is widely prescribed for colorectal cancer, lung cancer, glioblastoma, and other malignancies. Strong physician confidence, broad regulatory approvals, and favorable treatment outcomes have supported widespread adoption. The availability of biosimilars has improved accessibility and strengthened market penetration across various regions. Growing patient awareness regarding targeted cancer therapies has further supported demand. Hospitals and specialty oncology centers continue to utilize Avastin as a key component of treatment regimens. Ongoing research evaluating combination therapies and expanded indications is also contributing to segment growth. These factors collectively reinforced Avastin’s leading position in the market.

The Inlyta segment is expected to witness the fastest CAGR of 8.3% from 2026 to 2033. Growth is driven by increasing use of targeted therapies in advanced cancer treatment and expanding clinical applications. The drug is gaining traction due to its effectiveness in managing renal cell carcinoma and other cancers. Growing emphasis on personalized medicine and precision oncology is supporting adoption. Rising investments in oncology drug development and favorable clinical outcomes are accelerating demand. Continuous research efforts and regulatory approvals for expanded indications are expected to create new growth opportunities. Increasing healthcare expenditure and improved access to advanced therapies across emerging markets are further contributing to growth. These factors position Inlyta as the fastest-growing drug segment during the forecast period.

• By Route of Administration

On the basis of route of administration, the Angiogenesis Inhibitors Market is segmented into Oral, Parenteral, and Others. The Parenteral segment dominated the market with a 72.64% share in 2025 due to the widespread use of injectable biologics and monoclonal antibodies in cancer treatment. Most approved angiogenesis inhibitors are administered intravenously under clinical supervision, supporting high utilization of this route. The segment benefits from rapid drug delivery, improved bioavailability, and enhanced therapeutic effectiveness. Hospitals and specialty cancer centers prefer parenteral administration for advanced oncology therapies. Growing adoption of biologic drugs and increasing patient volumes in oncology departments have strengthened segment growth. Expanding healthcare infrastructure and rising cancer incidence globally continue to support demand. These factors collectively contributed to the dominant market position of the parenteral segment.

The Oral segment is projected to register the fastest CAGR of 7.6% from 2026 to 2033. Growth is driven by increasing patient preference for convenient treatment options and advancements in oral targeted therapies. Oral formulations offer improved treatment adherence and reduce the need for frequent hospital visits. Pharmaceutical companies are investing in the development of novel oral anti-angiogenic agents to enhance patient convenience and accessibility. Expanding adoption of home-based treatment approaches and supportive healthcare policies are further driving demand. Increasing availability of oral oncology drugs and growing acceptance among healthcare providers are expected to support segment growth. These factors are anticipated to accelerate expansion of the oral administration segment.

• By End-Users

On the basis of end-users, the Angiogenesis Inhibitors Market is segmented into Hospitals, Specialty Clinics, and Others. The Hospitals segment dominated the market with a 58.47% share in 2025 due to the high volume of cancer patients receiving treatment in hospital settings. Hospitals possess advanced oncology infrastructure, specialized healthcare professionals, and access to complex biologic therapies. The segment benefits from increasing cancer diagnosis rates and growing demand for comprehensive treatment services. Availability of infusion facilities and multidisciplinary cancer care teams further supports adoption. Rising healthcare expenditure and expanding oncology departments across major healthcare institutions continue to strengthen segment growth. Hospitals also participate actively in clinical trials and advanced treatment programs. These factors collectively contributed to the segment’s dominant position in 2025.

The Specialty Clinics segment is expected to witness the fastest CAGR of 7.7% from 2026 to 2033. Growth is driven by increasing demand for specialized cancer care services and personalized treatment approaches. Specialty clinics provide focused oncology expertise, shorter waiting times, and improved patient management. Rising investments in dedicated cancer treatment centers and expanding access to advanced therapies are supporting growth. Increasing patient preference for outpatient care settings and advancements in targeted therapies are further driving adoption. Growing healthcare infrastructure development across emerging economies is also contributing to segment expansion. These factors are expected to support strong growth throughout the forecast period.

• By Distribution Channel

On the basis of distribution channel, the Angiogenesis Inhibitors Market is segmented into Hospital Pharmacy, Retail Pharmacy, and Others. The Hospital Pharmacy segment dominated the market with a 55.18% share in 2025 due to the high utilization of angiogenesis inhibitors in hospital-based oncology treatment programs. Hospital pharmacies play a critical role in dispensing biologics, monoclonal antibodies, and other advanced cancer therapies. The segment benefits from strong integration with oncology departments and specialized treatment centers. Increasing patient admissions for cancer treatment and growing use of infusion-based therapies continue to support demand. Hospitals maintain strict drug storage, handling, and administration standards, further strengthening their role in distribution. Expanding healthcare infrastructure and rising cancer prevalence globally also contribute to segment growth. These factors collectively supported the dominant position of hospital pharmacies in 2025.

The Retail Pharmacy segment is projected to register the fastest CAGR of 7.5% from 2026 to 2033. Growth is driven by increasing availability of oral angiogenesis inhibitors and growing patient preference for convenient access to medications. Expanding retail pharmacy networks and improved distribution systems are supporting market expansion. Rising adoption of outpatient cancer treatment approaches and increasing healthcare accessibility are further driving demand. Retail pharmacies are enhancing oncology drug availability through partnerships with pharmaceutical companies and healthcare providers. Growing awareness regarding targeted therapies and improved reimbursement coverage are also contributing to growth. These factors are expected to accelerate expansion of the retail pharmacy segment during the forecast period.

Angiogenesis Inhibitors Market Regional Analysis

North America dominated the Angiogenesis Inhibitors market and accounted for the largest revenue share of 38.92% in 2025, supported by strong adoption of targeted oncology therapies, advanced healthcare infrastructure, and significant investments in cancer research and drug development. The region benefits from the presence of leading pharmaceutical and biotechnology companies, favorable reimbursement frameworks, and high awareness regarding innovative cancer treatments. Increasing prevalence of cancer, growing use of biologics, and expanding clinical trial activities continue to strengthen North America's leadership position in the global market.

U.S. Angiogenesis Inhibitors Market Insight

The U.S. Angiogenesis Inhibitors market is witnessing strong growth due to the rising incidence of cancer, increasing adoption of precision medicine, and substantial investments in oncology research. The country's well-established healthcare system and strong presence of major pharmaceutical companies support the development and commercialization of advanced anti-angiogenic therapies. In addition, favorable regulatory approvals, growing utilization of targeted therapies, and expanding clinical trial activities are accelerating market growth across the country.

Europe Angiogenesis Inhibitors Market Insight

The Europe Angiogenesis Inhibitors market remains a major contributor to global revenue, driven by increasing cancer prevalence, strong healthcare systems, and growing adoption of targeted oncology treatments. The region benefits from supportive government healthcare programs, extensive research activities, and rising investments in innovative cancer therapies. Growing demand for biologics and continuous advancements in oncology treatment protocols continue to support market expansion across Europe.

U.K. Angiogenesis Inhibitors Market Insight

The U.K. Angiogenesis Inhibitors market is experiencing steady growth, supported by increasing cancer diagnosis rates, rising healthcare expenditure, and growing access to advanced targeted therapies. Strong research capabilities, expanding oncology clinical trials, and the presence of leading academic institutions are contributing to market development. Furthermore, increasing focus on precision medicine and personalized cancer treatment approaches is driving the adoption of angiogenesis inhibitors across the country.

Germany Angiogenesis Inhibitors Market Insight

The Germany Angiogenesis Inhibitors market is expanding steadily due to its advanced healthcare infrastructure, strong pharmaceutical industry presence, and growing investments in oncology research. The country continues to witness increasing adoption of biologics and targeted cancer therapies across hospitals and specialty treatment centers. Continuous innovation in cancer treatment and favorable reimbursement support are further contributing to market growth in Germany.

Asia-Pacific Angiogenesis Inhibitors Market Insight

The Asia-Pacific Angiogenesis Inhibitors market is expected to witness the fastest growth at a CAGR of 7.8% from 2026 to 2033, driven by rising cancer prevalence, improving healthcare infrastructure, and increasing access to advanced biologic therapies across China, India, and Japan. Growing healthcare expenditure, expanding patient awareness, and increasing government initiatives focused on cancer care are supporting regional market expansion. In addition, the growing presence of pharmaceutical manufacturers and increasing investments in oncology research are accelerating market growth throughout the region.

Japan Angiogenesis Inhibitors Market Insight

The Japan Angiogenesis Inhibitors market is witnessing consistent growth due to rising demand for targeted cancer therapies, increasing healthcare spending, and strong investments in pharmaceutical innovation. The country's advanced healthcare system and growing focus on precision medicine are supporting the adoption of anti-angiogenic treatments. Moreover, increasing clinical research activities and an aging population with a higher cancer burden are contributing to market growth.

China Angiogenesis Inhibitors Market Insight

The China Angiogenesis Inhibitors market is growing rapidly, driven by increasing cancer incidence, expanding healthcare coverage, and rising adoption of innovative oncology therapies. Government initiatives to improve cancer treatment accessibility, growing investments in biotechnology research, and expanding pharmaceutical manufacturing capabilities are significantly boosting market demand. In addition, increasing awareness regarding targeted therapies and continuous healthcare infrastructure development are positioning China as one of the fastest-growing markets for angiogenesis inhibitors globally.

Angiogenesis Inhibitors Market Share

The Angiogenesis Inhibitors industry is primarily led by well-established companies, including:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Amgen Inc. (U.S.)
• Pfizer Inc. (U.S.)
• Bayer AG (Germany)
• Novartis AG (Switzerland)
• Bristol Myers Squibb Company (U.S.)
• Merck & Co., Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• Sanofi S.A. (France)
• AstraZeneca PLC (U.K.)
• Regeneron Pharmaceuticals, Inc. (U.S.)
• Takeda Pharmaceutical Company Limited (Japan)
• AbbVie Inc. (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• GSK plc (U.K.)
• Boehringer Ingelheim International GmbH (Germany)
• Eisai Co., Ltd. (Japan)
• Exelixis, Inc. (U.S.)
• Genentech, Inc. (U.S.)
• BioNTech SE (Germany)
• Ono Pharmaceutical Co., Ltd. (Japan)
• Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China)
• BeiGene, Ltd. (China)
• Innovent Biologics, Inc. (China)
• Cipla Limited (India)
• Dr. Reddy’s Laboratories Ltd. (India)
• Sun Pharmaceutical Industries Ltd. (India)
• Lupin Limited (India)
• Zydus Lifesciences Limited (India)
• Aurobindo Pharma Limited (India)
• Intas Pharmaceuticals Ltd. (India)
• Biocon Limited (India)
• Celltrion, Inc. (South Korea)
• Samsung Bioepis Co., Ltd. (South Korea)

Latest Developments in Angiogenesis Inhibitors Market

• In November 2023, the U.S. FDA approved FRUZAQLA (fruquintinib) from Takeda Pharmaceutical Company and HUTCHMED for the treatment of previously treated metastatic colorectal cancer (mCRC). Fruquintinib is a highly selective inhibitor of VEGFR-1, VEGFR-2, and VEGFR-3 and became the first targeted therapy approved in more than a decade for mCRC regardless of biomarker status or prior therapies. The approval was based on positive Phase III FRESCO and FRESCO-2 trial results demonstrating improved overall survival and progression-free survival
• In May 2023, Takeda Pharmaceutical Company and HUTCHMED announced that the FDA granted Priority Review to the New Drug Application (NDA) for fruquintinib for previously treated metastatic colorectal cancer. The submission included data from the Phase III FRESCO and FRESCO-2 studies and highlighted growing regulatory support for next-generation angiogenesis inhibitors targeting VEGF pathways
• In January 2022, Genentech (Roche Group) received U.S. FDA approval for Vabysmo (faricimab-svoa), the first bispecific antibody designed to inhibit both VEGF-A and Angiopoietin-2 (Ang-2) pathways. Approved for wet age-related macular degeneration and diabetic macular edema, the launch represented a significant advancement in angiogenesis-targeted therapies and demonstrated expanding applications of anti-angiogenic treatments beyond oncology
• In January 2023, the U.S. FDA granted accelerated approval to Tukysa (tucatinib) in combination with trastuzumab for HER2-positive metastatic colorectal cancer previously treated with an anti-VEGF monoclonal antibody. The approval reflected continued expansion of targeted treatment strategies in colorectal cancer management, a key therapeutic area for angiogenesis inhibitors
• In April 2024, the U.S. FDA announced the approval of its 50th biosimilar product, marking a significant milestone for biologic therapies. The continued expansion of biosimilars, including biosimilars referencing anti-VEGF therapies such as bevacizumab, is expected to improve patient access to angiogenesis inhibitor treatments while reducing healthcare costs globally
• In June 2024, the U.S. FDA approved Bristol Myers Squibb's Krazati (adagrasib) in combination with cetuximab for KRAS G12C-mutated colorectal cancer. Although not a direct angiogenesis inhibitor, the approval highlights the growing trend toward combination targeted therapies in colorectal cancer, one of the largest indications utilizing anti-angiogenic treatment regimens
• In May 2024, the U.S. FDA finalized the withdrawal of approval for Truseltiq (infigratinib) for previously treated cholangiocarcinoma following challenges in completing confirmatory studies. The event highlighted increasing regulatory emphasis on post-marketing evidence and clinical benefit verification for targeted oncology therapies, including agents affecting angiogenic pathways

SKU-52558